Akili (NASDAQ:AKLI – Get Rating) had its price target boosted by Morgan Stanley from $2.00 to $3.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an "equal weight" rating on the stock. Morgan Stanley's price objective would suggest a potential upside of 115.83% from the company's previous close.

Several other equities analysts have also recently issued reports on the stock. Credit Suisse Group boosted their price target on shares of Akili from $4.00 to $4.50 and gave the company an "outperform" rating in a research report on Tuesday, November 15th. Bank of America initiated coverage on shares of Akili in a report on Friday, November 18th. They issued a "neutral" rating on the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Akili presently has a consensus rating of "Moderate Buy" and a consensus target price of $3.75.

Akili Stock Performance

AKLI stock opened at $1.39 on Wednesday. The company has a 50-day moving average price of $1.37. Akili has a 12-month low of $0.86 and a 12-month high of $37.58. The company has a debt-to-equity ratio of 0.11, a quick ratio of 12.27 and a current ratio of 12.27.

Institutional Trading of Akili

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC purchased a new position in Akili during the third quarter valued at $32,000. Longitude Cayman Ltd. bought a new position in Akili during the third quarter valued at $34,000. Northeast Financial Consultants Inc bought a new position in Akili during the third quarter valued at $128,000. YHB Investment Advisors Inc. lifted its position in Akili by 25.7% during the fourth quarter. YHB Investment Advisors Inc. now owns 116,430 shares of the company's stock valued at $130,000 after purchasing an additional 23,830 shares during the last quarter. Finally, Revelation Capital Management LLC bought a new position in Akili during the third quarter valued at $556,000. 77.97% of the stock is owned by hedge funds and other institutional investors.

Akili Company Profile

(Get Rating)

Akili, Inc, a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.

Featured Articles

• Get a free copy of the StockNews.com research report on Akili (AKLI)
• The Future Of E-Commerce: Analysis And New Data
• Chevron Delights Shareholders with $75 Billion in Share Buybacks
• Levi Strauss Is A Good Fit For Income Investors
• 3 Small Caps That Have Big Upside
• Mullen Automotive: The Good News, The Bad And The Ugly Outlook

Receive News & Ratings for Akili Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akili and related companies with MarketBeat.com's FREE daily email newsletter.